Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:11254199rdf:typepubmed:Citationlld:pubmed
pubmed-article:11254199lifeskim:mentionsumls-concept:C0086418lld:lifeskim
pubmed-article:11254199lifeskim:mentionsumls-concept:C0302908lld:lifeskim
pubmed-article:11254199lifeskim:mentionsumls-concept:C0809874lld:lifeskim
pubmed-article:11254199lifeskim:mentionsumls-concept:C0037813lld:lifeskim
pubmed-article:11254199lifeskim:mentionsumls-concept:C1880022lld:lifeskim
pubmed-article:11254199pubmed:issue1lld:pubmed
pubmed-article:11254199pubmed:dateCreated2001-3-19lld:pubmed
pubmed-article:11254199pubmed:abstractTextThe tetrapeptide AcSDKP, a natural and specific substrate of angiotensin I-converting enzyme (ACE), is a negative regulator of hematopoiesis. AcSDKP has been measured in various biological media using an enzyme immunoassay (EIA), but its presence in human plasma and urine has not been formally established. By using immunoaffinity extraction and liquid chromatography-electrospray mass spectrometry, we demonstrate that AcSDKP-like immunoreactivity measured with EIA in plasma and urine samples from untreated, captopril- (an ACE inhibitor) and AcSDKP-treated subjects corresponds to AcSDKP. The present study confirms that AcSDKP is naturally present in human plasma and urine and that EIA is reliable for its measurement in such media.lld:pubmed
pubmed-article:11254199pubmed:languageenglld:pubmed
pubmed-article:11254199pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11254199pubmed:citationSubsetIMlld:pubmed
pubmed-article:11254199pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11254199pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11254199pubmed:statusMEDLINElld:pubmed
pubmed-article:11254199pubmed:monthMarlld:pubmed
pubmed-article:11254199pubmed:issn1387-2273lld:pubmed
pubmed-article:11254199pubmed:authorpubmed-author:GrognetJ MJMlld:pubmed
pubmed-article:11254199pubmed:authorpubmed-author:CréminonCClld:pubmed
pubmed-article:11254199pubmed:authorpubmed-author:EzanEElld:pubmed
pubmed-article:11254199pubmed:authorpubmed-author:PruvostAAlld:pubmed
pubmed-article:11254199pubmed:authorpubmed-author:BenechHHlld:pubmed
pubmed-article:11254199pubmed:authorpubmed-author:JunotCClld:pubmed
pubmed-article:11254199pubmed:issnTypePrintlld:pubmed
pubmed-article:11254199pubmed:day5lld:pubmed
pubmed-article:11254199pubmed:volume752lld:pubmed
pubmed-article:11254199pubmed:ownerNLMlld:pubmed
pubmed-article:11254199pubmed:authorsCompleteYlld:pubmed
pubmed-article:11254199pubmed:pagination69-75lld:pubmed
pubmed-article:11254199pubmed:dateRevised2004-11-17lld:pubmed
pubmed-article:11254199pubmed:meshHeadingpubmed-meshheading:11254199...lld:pubmed
pubmed-article:11254199pubmed:meshHeadingpubmed-meshheading:11254199...lld:pubmed
pubmed-article:11254199pubmed:meshHeadingpubmed-meshheading:11254199...lld:pubmed
pubmed-article:11254199pubmed:meshHeadingpubmed-meshheading:11254199...lld:pubmed
pubmed-article:11254199pubmed:meshHeadingpubmed-meshheading:11254199...lld:pubmed
pubmed-article:11254199pubmed:year2001lld:pubmed
pubmed-article:11254199pubmed:articleTitleCharacterization of immunoreactive acetyl-Ser-Asp-Lys-Pro in human plasma and urine by liquid chromatography-electrospray mass spectrometry.lld:pubmed
pubmed-article:11254199pubmed:affiliationService de Pharmacologie et d'Immunologie, DSV/DRM, CEA/Saclay, Gif-sur-Yvette, France.lld:pubmed
pubmed-article:11254199pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:11254199pubmed:publicationTypeClinical Triallld:pubmed